1472-8214
Quarterly
No
1744-7623
EXPERT OPIN EMERG DR
2001
28
ENGLAND
http://www.tandfonline.com/loi/iemd20
>12周,或约稿审稿时间
3区中科院分区
较易平均录用比例
2.7影响因子
药学小学科
164/352JIF RANK
897总被引频次
月期刊平台服务过的文章录用时间为1-3个月,依据20年经验,经月期刊专家预审通过后的文章,投稿通过率100%以上!
关于新兴药物的专家意见提供了最快速发展的药物类别和治疗领域的专家评估。由主要专家编写的新兴药物简介是权威的、全面的和最新的。新兴药物的专家意见是必不可少的阅读医药和学术科学家,研究规划,医药产品经理,临床意见领袖和医疗保健规划。制定关于新兴药物的专家意见的目的是对最重要的新兴药物技术提供专家评价。这些评估是根据它们对当前特定疾病管理的潜在影响。关于新兴药物的专家意见还包括关于新兴药物发展战略的论文,其目的是对最有希望的药物研究领域的商业和技术可行性提供一种可获得和独立的评估。
Expert Opinion on Emerging Drugs provides an expert assessment of the most rapidly advancing drug classes and therapeutic areas. Emerging Drugs profiles, prepared by leading experts, are authoritative, comprehensive and up-to date. Expert Opinion on Emerging Drugs is essential reading for pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners. Expert Opinion on Emerging Drugs was devised with the intention of providing an expert evaluation of the most important emerging drug technologies. These are assessed in terms of their potential impact on the current management of specific diseases. Expert Opinion on Emerging Drugs also includes papers on Emerging Drug Development Strategies, which aim to provide an accessible and independent assessment of the commercial and technical viability of the most promising areas of drug research.
大类学科 | 分区 | 小类学科 | 分区 | Top期刊 | 综述期刊 |
医学 | 2区 | PHARMACOLOGY & PHARMACY 药学 | 2区 | 否 | 是 |
JCR分区等级 | JCR所属学科 | 分区 | 影响因子 |
Q2 | PHARMACOLOGY & PHARMACY | Q2 | 3.912 |
CiteScore | SJR | SNIP | 学科类别 | 分区 | 排名 | 百分位 |
5.60 | 0.972 | 0.795 | 大类:Medicine 小类:Pharmacology (medical) | Q2 | 66 / 255 |
74% |
大类:Medicine 小类:Pharmacology | Q2 | 110 / 303 |
63% |
影响因子 | h-index | Gold OA文章占比 | 研究类文章占比 | OA开放访问 | 平均审稿速度 |
3.912 | 43 | 3.41% | 9.68% | 未开放 | >12周,或约稿 |